Optimizing lipid lowering in patients at risk

Clinical Cardiology

Volumn 27, Issue 6, 2004, Pages

  Clark, Luther T ^a  

^a SUNY DOWNSTATE MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; C REACTIVE PROTEIN; CHYLOMICRON; COLESEVELAM; EZETIMIBE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PHYTOSTEROL; PRAVASTATIN; SIMVASTATIN;

CHOLESTEROL TRANSPORT; CORONARY RISK; DRUG INDICATION; HUMAN; HYPERLIPIDEMIA; INTESTINE ABSORPTION; ISCHEMIC HEART DISEASE; LOW FAT DIET; REVIEW; RISK REDUCTION; TREATMENT PLANNING;

EID: 2642527186     PISSN: 01609289     EISSN: None     Source Type: Journal    
DOI: 10.1002/clc.4960271507     Document Type: Review

References (34)

1. Scandinavian Simvastatin Survival Group: Randomised trial of cholesterol lowering in 4,444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344:1383-1389
2. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, Macfarlane PW, McKillop JH, Packard CJ, for the West of Scotland Coronary Prevention Study Group: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333:1301-1307
3. Sacks FM, Pfeffer MA, Moyé LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JMO, Wun C-C, Davis BR, Braunwald E, for the Cholesterol and Recurrent Events Trial Investigators: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996;335:1001-1009
4. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group: Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339: 1349-1357
5. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, Langendorfer A, Stein EA, Kruyer W, Gotto AM Jr: Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS. J Am Med Assoc 1988;279:1615-1622
6. Pearson TA, Laurora I, Chu H, Kafonek S: The Lipid Treatment Assessment Project (L-TAP): A multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med 2000;160:459-467
7. National Institutes of Health, U.S. Dept. of Health and Human Services; 1993. NIH publication 93-3096. National Center for Health Statistics: National Health and Nutrition Examination Survey (III). Atlanta, Ga.: Centers for Disease Control and Prevention, 1994
8. Straka RJ, Taheri R, Cooper SL, Tan AWH, Smith JC: Assessment of hypercholesterolemia control in a managed care organization. Pharmacotherapy 2001;21:818-827
9. Heart Protection Study Collaborative Group: MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomised placebo-controlled trial. Lancet 2002;360:7-22
10. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, Joyal SV, Hill KA, Pfeffer MA, Skene AM: Comparison of intensive and moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004;350:1-10
11. Nissen SE, Tuzcu EM, Schoenhagen P, Brown BG, Ganz P, Vogel RA, Crowe T, Howard G, Cooper CJ, Brodie B, Grines CL, DeMaria AN; REVERSAL Investigators: Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: A randomized controlled trial. J Am Med Assoc 2004;291:1071-1080
12. Jones P, Kafonek S, Laurora I, Hunninghake D, for the CURVES Investigators: Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am J Cardiol 1998;81:582-587
13. Foley KA, Simpson RJ Jr, Crouse JR III, Weiss TW, Markson LE, Alexander CM: Effectiveness of statin titration on low-density lipoprotein cholesterol goal attainment in patients at high risk of atherogenic events. Am J Cardiol 2003;92:79-81.
14. Sudhop T, Lutjohann D, Kodal A, Igel M, Tribble DL, Shah S, Perevozskaya I, von Bergmann K: Inhibition of intestinal cholesterol absorption by ezetimibe in humans. Circulation 2002;106:1943-1948
15. Knapp HH, Schrott H, Ma P, Knopp R, Chin B, Gaziano JM, Donovan JM, Burke SK, Davidson MH: Efficacy and safety of combination simvastatin and colesevelam in patients with primary hypercholesterolemia. Am J Med 2001;110:352-360
16. Davidson MH, McGarry T, Bettis R, Melani L, Lipka LJ, LeBeaut AP, Suresh R, Sun S, Veltri EP, on behalf of the Ezetimibe Study Group: Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia. J Am Coll Cardiol 2002;40: 2125-2134
17. Ballantyne CM, Houri J, Notarbartolo A, Melani L, Lipka LJ, Suresh R, Sun S, LeBeaut AP, Sager PT, Veltri EP, for the Ezetimibe Study Group: Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia. A prospective, randomized, double-blind trial. Circulation 2003;107:2409-2415
18. Melani L, Mills R, Hassman D, Lipetz R, Lipka L, LeBeaut A, Suresh R, Mukhopadhyay P, Veltri E: Efficacy and safety of ezetimibe coadministered with pravastatin in patients with primary hypercholesterolemia: A prospective, randomized, double-blind trial. Eur Heart J 2003;24:717-728
19. Kerzner B, Corbelli J, Sharp S, Lipka LJ, Melani L, LeBeaut A, Suresh R, Mukhopadhyay P, Veltri EP: Efficacy and safety of ezetimibe coadministered with lovastatin in primary hypercholesterolemia. Am J Cardiol 2003;91:418-424
20. Gagne C, Bays HE, Weiss SR, Mata P, Quinto K, Melino M, Cho M, Musliner TA, Gumbiner B, for the Ezetimibe Study Group: Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia. Am J Cardiol 2002;90:1084-1091
21. Goldberg AC, Capece R, Sapre A, Liu J, Mitchel Y: Efficacy of ezetimibe 10 mg/day coadministered with multiple doses of simvastatin in patients with primary hypercholesterolemia (abstr 1084-1174). J Am Coll Cardiol 2004;42(suppl A):480A
22. Ballantyne CM, Blazing MA, King TR, Brady WE, Palmisano J: Efficacy of ezetimibe coadministered with simvastatin vs. atorvastatin in patients with hypercholesterolemia (abstr 1084-1176). J Am Coll Cardiol 2004;42(suppl A):480A
23. Proctor SD, Mamo JC: Retention of fluorescent-labeled chylomicron remnants within the intima of the arterial wall-evidence that plaque cholesterol may be derived from post-prandial lipoproteins. Eur J Clin Invest 1998;28:497-503
24. Dane-Stewart CA, Watts GF, Barrett PH, Stuckey BG, Mamo JC, Martins IJ, Redgrave TG: Chylomicron remnant metabolism studied with a new breath test in postmenopausal women with and without type 2 diabetes mellitus. Clin Endocrinol 2003;58:415-420
25. van Heek M, Compton DS, Davis HR: The cholesterol absorption inhibitor, ezetimibe, decreases diet-induced hypercholesterolemia in monkeys. Eur J Pharmacol 2001;415:79-84
26. Sudhop T, Gottwald BM, von Bergmann K: Serum plant sterols as a potential risk factor for coronary heart disease. Metabolism 2002; 51:1519-1521
27. Assmann G, Cullen P, Erbey JR, Ramey DR, Kannenberg F, Schulte H: Elevation in plasma sitosterol concentration is associated with an increased risk for coronary events in the PROCAM study (abstr). Circulation 2003;108:IV-730
28. Salen G, von Bergmann K, Lütjohann D, Kwiterovich P, Kane J, Patel SB, Musliner T, Stein P, Musser B: Ezetimibe effectively reduces plasma plant sterols in patients with sitosterolemia. Circulation 2004;109:966-971
29. Assmann G, Kannenberg F, Weng W, Erbey J, John A, Tribble D, Musliner T, Lipka LJ, Veltri EP: Effects of ezetimibe, simvastatin, and ezetimibe-simvastatin on non-cholesterol sterol (abstr 1008-1183). J Am Coll Cardiol 2004;42(suppl A):445A
30. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR: Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002; 347:1557-1565
31. Paul A, Ko KW, Li L, Yechoor V, McCrory MA, Szalai AJ, Chan L: C-reactive protein accelerates the progression of atherosclerosis in apolipoprotein E-deficient mice. Circulation 2004;109:647-655.
32. Sager PT, Melani L, Lipka L, Strony J, Yang B, Suresh R, Veltri E, for the Ezetimibe Study Group: Effect of coadministration of ezetimibe and simvastatin on high-sensitivity C-reactive protein. Am J Cardiol 2003;92:1414-1418
33. Brookes L: Latest results with new lipid-lowering therapies. Available at: www.thaiheart.org/pdf/latest%20Results%20With%20New%20Lipid.pdf. Accessed Match 24, 2004
34. Study of Heart and Renal Protection (SHARP): Background information for International Coordinating Centre Candidates. Available at: http://www.ctsu.ox.ac.uk/~jobs/sharpbg.htm. Accessed March 24, 2004